Helen M. Thackray's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 7,525 Common Stock done at an average price of $7.5 . Disclosure was reported to the exchange on March 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.50 per share. | 31 Mar 2025 | 7,525 | 377,318 (0%) | 0% | 7.5 | 56,438 | Common Stock |
| Biocryst Pharmaceuticals Inc. | M. Helen Thackray | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 260,950 | 260,950 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Thackray Helen M. | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 125,950 | 390,939 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Thackray M. Helen | Chief R&D Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.39 per share. | 19 Dec 2024 | 6,096 | 384,843 (0%) | 0% | 7.4 | 45,049 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.53 per share. | 14 Dec 2024 | 7,150 | 264,989 (0%) | 0% | 7.5 | 53,840 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Purchase of securities on an exchange or from another person at price $ 5.86 per share. | 14 May 2024 | 30,000 | 272,139 (0%) | 0% | 5.9 | 175,800 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.08 per share. | 31 Mar 2024 | 7,525 | 242,139 (0%) | 0% | 5.1 | 38,227 | Common Stock |
| Immunogen, Inc. | M. Thackray Helen | Director | Grant, award, or other acquisition of securities at price $ 29.65 per share. | 29 Dec 2023 | 252 | 3,074 (0%) | 0% | 29.7 | 7,472 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.05 per share. | 19 Dec 2023 | 5,580 | 249,664 (0%) | 0% | 6.1 | 33,759 | Common Stock |
| Biocryst Pharmaceuticals Inc. | M. Thackray Helen | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 238,000 | 238,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Helen Thackray M. | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 51,000 | 258,275 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | M. Thackray Helen | Chief R&D Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.43 per share. | 14 Dec 2023 | 3,031 | 255,244 (0%) | 0% | 6.4 | 19,489 | Common Stock |
| Immunogen, Inc. | Helen M. Thackray | Director | Grant, award, or other acquisition of securities at price $ 18.87 per share. | 30 Jun 2023 | 397 | 2,350 (0%) | 0% | 18.9 | 7,491 | Common Stock |
| Immunogen, Inc. | Helen M. Thackray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 19,597 | 19,597 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Helen M. Thackray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 13,090 | 13,090 | - | - | Restricted Stock Unit | |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 8.29 per share. | 03 Apr 2023 | 7,000 | 207,275 (0%) | 0% | 8.3 | 58,030 | Common Stock |
| Immunogen, Inc. | Helen M. Thackray | Director | Grant, award, or other acquisition of securities at price $ 3.84 per share. | 31 Mar 2023 | 1,953 | 1,953 (0%) | 0% | 3.8 | 7,500 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 238,000 | 238,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 81,000 | 214,275 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 10.89 per share. | 15 Dec 2022 | 3,125 | 133,275 (0%) | 0% | 10.9 | 34,031 | Common Stock |
| Immunogen, Inc. | Helen M. Thackray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 32,066 | 32,066 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Helen M. Thackray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 10,932 | 40,932 | - | - | Deferred Share Unit | |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 16.20 per share. | 01 Apr 2022 | 7,600 | 136,400 (0%) | 0% | 16.2 | 123,120 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 205,000 | 205,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 44,000 | 144,000 (0%) | 0% | 0 | Common Stock | |
| Immunogen, Inc. | Helen M. Thackray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Helen M. Thackray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 30,000 | 30,000 | - | - | Deferred Share Unit | |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Director, Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 400,000 | 400,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Helen M. Thackray | Director, Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| GlycoMimetics Inc | Helen M. Thackray | SVP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 69,000 | 69,000 | - | - | Employee Stock Option (right to buy) | |
| GlycoMimetics Inc | Helen M. Thackray | SVP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 34,500 | 183,115 (0%) | 0% | 0 | Common Stock |